Carisma Therapeutics: First-of-its-kind engineered macrophage cell therapy platform shows ability to reduce tumor burden & activate anti-tumor immunity, improving overall survival in pre-clinical cancer models24. March 2020|In Portfolio News|By eazee-designstudioNature Biotechnology has published a study demonstrating Carisma’s foundational technology evaluating the potential of human chimeric antigen receptor macrophages (CAR-M) for cancer immunotherapy. The preclinical findings indicate that CAR-M therapy could overcome the key challenges that cell therapies have encountered with solid tumors – limited trafficking to the tumor site, an immunosuppressive tumor microenvironment, and the heterogeneous expression of tumor-associated antigens. PrevNext
